{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sousa TDC"],"funding":["Conselho Nacional de Desenvolvimento Científico e Tecnológico","Coordenação de Aperfeiçoamento de Pessoal de Nível Superior","Ministério da Saúde"],"pagination":["944277"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9516282"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["The influenza A virus (IAV) is of a major public health concern as it causes annual epidemics and has the potential to cause pandemics. At present, the neuraminidase inhibitors (NAIs) are the most widely used anti-influenza drugs, but, more recently, the drug baloxavir marboxil (BXM), a polymerase inhibitor, has also been licensed in some countries. Mutations in the viral genes that encode the antiviral targets can lead to treatment resistance. Worldwide, a low prevalence of antiviral resistant strains has been reported. Despite that, this situation can change rapidly, and resistant strain surveillance is a priority. Thus, the aim of this was to evaluate Brazilian IAVs antiviral resistance from 2017 to 2019 through the identification of viral mutations associated with reduced inhibition of"],"journal":["Frontiers in public health"],"pubmed_title":["Low prevalence of influenza A strains with resistance markers in Brazil during 2017-2019 seasons."],"pmcid":["PMC9516282"],"funding_grant_id":["401851/2015-0"],"pubmed_authors":["Rodrigues RR","Motta F","Martins JSCC","de Almeida WAF","Garcia CC","Siqueira MM","Brown D","Resende PC","Debur MDC","Santos KCO","Cavalcanti AC","Gregianini TS","Ferreira JA","Santos CA","Fernandes SB","Sousa TDC","Pereira FM","Miranda MD","Matos ADR","Iani FCM"],"additional_accession":[]},"is_claimable":false,"name":"Low prevalence of influenza A strains with resistance markers in Brazil during 2017-2019 seasons.","description":"The influenza A virus (IAV) is of a major public health concern as it causes annual epidemics and has the potential to cause pandemics. At present, the neuraminidase inhibitors (NAIs) are the most widely used anti-influenza drugs, but, more recently, the drug baloxavir marboxil (BXM), a polymerase inhibitor, has also been licensed in some countries. Mutations in the viral genes that encode the antiviral targets can lead to treatment resistance. Worldwide, a low prevalence of antiviral resistant strains has been reported. Despite that, this situation can change rapidly, and resistant strain surveillance is a priority. Thus, the aim of this was to evaluate Brazilian IAVs antiviral resistance from 2017 to 2019 through the identification of viral mutations associated with reduced inhibition of","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-04-08T11:46:33.005Z","creation":"2024-12-03T20:25:25.215Z"},"accession":"S-EPMC9516282","cross_references":{"pubmed":["36187691"],"doi":["10.3389/fpubh.2022.944277"]}}